Atmeksi (methocarbamol) NDC 69528-701

NDC codes

FDA NDC Directory

Product NDC (as listed)69528-701Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69528-0701Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69528-701-05	69528070105	150 mL in 1 BOTTLE (69528-701-05)Marketed from Jan 15, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Atmeksi
Generic name (nonproprietary): methocarbamol
Active ingredients: Methocarbamol — 750 mg/5mL
Dosage form: Suspension
Route: Oral
Labeler: Rosemont Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 219843
Marketing start: Dec 22, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Centrally-mediated Muscle Relaxation (Physiologic effect)
Identifiers: Product ID 69528-701_4ce9560d-185c-1e28-e063-6294a90af77fSPL ID 4ce9560d-185c-1e28-e063-6294a90af77fSPL set ID 62de7345-613b-4838-96e5-aceca3cea6b2RxCUI 2729335, 2729341UNII 125OD7737X
Pharmacologic class: Muscle Relaxant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469528070105 followed by a unit qualifier and the quantity

Package 69528-0701-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 13, 2026.

Indications (excerpt from the label)

ATMEKSI (methocarbamol) oral suspension is a muscle relaxant indicated as: an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older. 1.1 Acute, painful musculoskeletal conditions. ATMEKSI is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)